Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Product Planning Spend Up to Half their Time on BD

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
A new survey of drug manufacturers found that new product planning teams dedicate upwards of 50% of their time on business development activities.

New product planning teams have taken on responsibilities beyond acting as a developing product’s commercial voice. The recent study published by Cutting Edge Information shows that among surveyed companies, 100% of new product planning teams are involved in business development. These activities range from generating commercial assessments to contributing to the go/no go decisions made by the business development function.

Company needs dictate the extent of new product planning involvement in these business development activities. Often, companies shift new product planning responsibilities and resources to reflect the current business quarter and the developing product’s timeline. While all surveyed companies leverage their NPP teams to provide initial input on upcoming business development deals, an estimated one third also use their teams either to identify potential opportunities early or to participate during the later decision making stages.

Companies benefit from incorporating the new product planning function into business development because new product planning teams are able to evaluate the commercial viability of a deal early and objectively. “New product planning teams use preliminary scientific evaluations and commercial profiles to provide business development teams with an unbiased perspective,” said David Richardson, research team manager at Cutting Edge Information. Consequently, new product planning support helps companies allocate their resources wisely and pursue advantageous pharma partnerships.

“Pharmaceutical New Product Planning: Building the Framework for Brand Commercialization,” (http://www.cuttingedgeinfo.com/research/portfolio-management/new-product-planning/) features detailed data on new product planning’s early commercialization efforts including team structure and reporting lines, budget and spending, staffing—encompassing staff education levels, background and compensation metrics—and business development efforts. This study is designed to help pharmaceutical companies:

•    Increase new product planning resources to support growing brand responsibilities as developing products move closer to launch.
•    Communicate and work with clinical teams to insert commercially focused data collection into clinical trials.
•    Facilitate easy transition of brand responsibility between teams by leveraging new product planning team members’ expertise.
•    Leverage new product planning teams’ scientific and commercial expertise and unbiased perspectives to support business development groups.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Patient Enrollment is a Critical Cost Driver in Phase 1 Clinical Trials
Cutting Edge Information’s recent study of oncology trials revealed a strong correlation between number of patients and trial cost.
Wednesday, June 19, 2013
Central and Eastern Europe Building Clinical Trial Success
Development teams benefit from tougher investigator standards and active patient populations, finds Cutting Edge Information.
Monday, February 14, 2011
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!